title: Clinical effects of leukofiltration and surface modification on post-cardiopulmonary bypass atrial fibrillation in different risk cohorts.
abstract: OBJECTIVE
  A manifestation of inflammatory injury to the heart, atrial fibrillation (AF), ranks among the most frequent and potentially life-threatening post-operative complications.
  
  
  METHODS
  In a prospective randomized study, 120 patients undergoing CABG were allocated into two groups (N = 60): Group 1: Polymethoxyethylacry late-coated circuits + Leukocyte filters (Terumo,USA); Group 2:
  
  
  METHODS
  Uncoated circuits (Terumo,USA). Each group was further divided into three subgroups (N = 20) with respect to low (Euroscore 0-2), medium (3-5) and high (6+) risk patients.
  
  
  RESULTS
  Serum IL-2 levels were significantly lower in the study group at T4 and T5 (p < 0.01). C3a levels showed significant differences in the leukofiltrated group at T4 and T5 (p < 0.05). CPKMB levels demonstrated well-preserved myocardium in the leukofiltration group, post-operatively. AF incidence was 10% (2 patients) in the study and 35% (7 patients) in the control cohorts (p < 0.05). Phagocytic capacity on fibers in filtered patients was significantly lower.
  
  
  CONCLUSIONS
  Leukofiltration and coating significantly reduce the incidence, ventricular rate, and duration of AF after CABG via modulation of systemic inflammatory response and platelet preservation in high risk groups.
authors.affiliation: Department of CV Surgery, University of Kirikkale, Ankara, Turkey. sgunaydin@isnet.net.tr
authors.forename: Serdar
authors.initials: S
authors.lastname: Gunaydin
authors.forename: Kamil
authors.initials: K
authors.lastname: Ayrancioglu
authors.forename: Erkan
authors.initials: E
authors.lastname: Dikmen
authors.forename: Kevin
authors.initials: K
authors.lastname: Mccusker
authors.forename: Venkataramana
authors.initials: V
authors.lastname: Vijay
authors.forename: Tamer
authors.initials: T
authors.lastname: Sari
authors.forename: Tevfik
authors.initials: T
authors.lastname: Tezcaner
authors.forename: Yaman
authors.initials: Y
authors.lastname: Zorlutuna
mesh_terms: D000818:Animals; D001281:Atrial Fibrillation / Q000517:prevention & control*; D001772:Blood Cell Count; D002315:Cardiopulmonary Bypass; D015331:Cohort Studies; D015926:Complement C3a / Q000032:analysis; D001026:Coronary Artery Bypass; D006331:Heart Diseases / Q000601:surgery; D006801:Humans; D007376:Interleukin-2 / Q000097:blood; D047589:Leukocyte Reduction Procedures; D007962:Leukocytes; D010976:Platelet Count; D011183:Postoperative Complications / Q000517:prevention & control*; D012307:Risk Factors
chemical_list: D007376:Interleukin-2; D015926:Complement C3a